Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a clinical-stage biotechnology company pioneering iPSC-derived cell therapies for cancer and autoimmune diseases. This page provides investors and industry observers with direct access to the company's official announcements, including clinical trial progress, financial results, and strategic collaborations.
Our curated news collection enables efficient tracking of material developments in IPSC's Allo-Evasion™ platform and pipeline candidates like CNTY-101. Users will find press releases covering FDA submissions, partnership agreements with leading research institutions, and presentations at major medical conferences.
Key updates include quarterly earnings reports, manufacturing advancements, intellectual property milestones, and peer-reviewed data publications. All content is sourced directly from Century Therapeutics' investor relations communications to ensure accuracy and timeliness.
Bookmark this page for streamlined monitoring of IPSC's progress in developing off-the-shelf cell therapies. Check regularly for updates on preclinical achievements, IND applications, and corporate developments shaping the future of regenerative medicine.
Century Therapeutics (NASDAQ: IPSC), a clinical-stage biotechnology firm, announced its participation in a fireside chat at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit on April 24, 2023, at 10:30 AM ET. The chat will feature Greg Russotti, Ph.D., serving as the ad-interim CEO. This event underscores Century's focus on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) aimed at treating cancer. The replay will be accessible for 30 days post-event on the company’s Investors page at centurytx.com. Century Therapeutics aims to address challenges in oncology by creating off-the-shelf therapies that enhance patient access and treatment efficacy, with a commitment to superior cell therapy technologies.
Century Therapeutics (NASDAQ: IPSC) announced key executive changes as of April 11, 2023. Greg Russotti, Ph.D., formerly the Chief Technology Officer, is now serving as the ad-interim Chief Executive Officer, succeeding Lalo Flores, Ph.D., who stepped down to pursue other opportunities. Additionally, Michael C. Diem, M.D., has been promoted to Chief Financial Officer, and Hy Levitsky, M.D., has rejoined the company as President of Research and Development. The Board of Directors is actively searching for a permanent CEO. Joe Jimenez, Chairman, highlighted Dr. Russotti's clinical and commercial expertise, emphasizing his capability to advance Century’s position in the cell therapy industry. The company maintains a solid balance sheet expected to fund operations into 2026, aiming to deliver innovative allogeneic cell therapies and target various cancers.
Century Therapeutics (NASDAQ: IPSC) reported significant developments in its Phase 1 ELiPSE-1 trial for CNTY-101 aimed at treating relapsed/refractory CD19 positive B-cell lymphomas. As of December 31, 2022, the company had cash, cash equivalents, and investments totaling $367.4 million, ensuring a financial runway through 2026. In 2022, the company recorded collaboration revenue of $5.2 million, while net cash provided by operations was $14.1 million. Research and development expenses rose to $97.2 million, contributing to a net loss of $130.9 million for the year. Full-year GAAP operating expenses are projected between $135 million and $145 million.
Century Therapeutics (NASDAQ: IPSC) announced preclinical data from its iPSC-based cell therapy platform will be presented at the AACR Annual Meeting on April 17, 2023. The poster, titled 'iPSC-derived CAR-NK cell therapy: nominating clinical candidate clones through integrated multi-functional analysis', features abstract number 2914 and will be presented by Michael Hall, PhD from the company. This clinical-stage biotechnology firm focuses on developing innovative cell therapies to target cancer, leveraging adult stem cells to provide improved treatment options and broader patient access. For more details, visit Century Therapeutics.
Century Therapeutics (NASDAQ: IPSC), a clinical-stage biotechnology firm, announced participation in two key investor conferences. The H.C. Wainwright Cell Therapy Virtual Conference will feature a fireside chat on February 28, 2023, at 10:30 AM ET. Additionally, the Cowen 43rd Annual Health Care Conference presentation is set for March 6, 2023, at 11:10 AM ET. Replays of both events will be accessible for 30 days via the company's website's “Events & Presentations” section. Century Therapeutics focuses on developing induced pluripotent stem cell-derived therapies to improve cancer treatment outcomes.
Century Therapeutics (NASDAQ: IPSC) has announced that the first patient has been dosed in the Phase 1 ELiPSE-1 trial of CNTY-101, a novel allogeneic cell therapy targeting relapsed or refractory CD19-positive B-cell lymphomas. This investigational therapy incorporates six precision gene edits, including a CD19 CAR and Allo-Evasion™ technology, designed to overcome immune rejection. The trial aims to assess CNTY-101's safety, tolerability, and preliminary efficacy through a unique multi-dosing strategy, potentially paving the way for innovative cell therapy treatments.
On February 1, 2023, Century Therapeutics (NASDAQ: IPSC) announced its participation in two upcoming investor conferences. The first event, The Guggenheim Healthcare Talks Oncology Day, is scheduled for February 8, 2023, at 3:55 PM ET. The second, The SVB Securities Global Biopharma Conference, will take place on February 15, 2023, at 11:20 AM ET. A replay of these events will be available on the company’s website for 30 days following the conferences. Century Therapeutics is focused on developing iPSC-derived cell therapies for cancer treatment, aiming to improve patient access and outcomes in oncology.
Century Therapeutics (NASDAQ: IPSC) has announced a strategic portfolio prioritization aimed at extending its cash runway into 2026. The company will focus on CNTY-101 for relapsed/refractory B-cell lymphoma and CNTY-107 for Nectin-4+ tumors, while de-prioritizing CNTY-103 for glioblastoma. A workforce reduction of approximately 25% has been implemented to support this strategy. The Phase 1 study of CNTY-101 remains on track, with no impact on the partnered programs with Bristol Myers Squibb. CEO Lalo Flores emphasizes the importance of these changes for achieving key development milestones.
Century Therapeutics (NASDAQ: IPSC) will have its CEO, Lalo Flores, present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:45 AM PT. As a biotechnology company specializing in iPSC-derived cell therapies for cancer treatment, Century aims to address the limitations of traditional therapies. A live webcast of the presentation will be available on their website, with a replay accessible for a limited time. For more company insights, visit Century Therapeutics.
Century Therapeutics (NASDAQ: IPSC) announced that CEO Lalo Flores, Ph.D., will engage in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 2:00 PM ET. A live webcast of the event will be accessible on the company's website, with an archived replay available for a limited time. The company focuses on developing iPSC-derived cell therapies to address cancer, leveraging advanced cellular reprogramming and genetic engineering. Their goal is to create off-the-shelf cell therapies that enhance patient access and improve cancer treatment outcomes.
